Clinical Scorecard: Evaluation of Background Parenchymal Enhancement Correlates with Lifetime Risk of Breast Cancer in MRI Screening

At a Glance

Key Highlights

• Mammography sensitivity is reduced in women with dense breast tissue; MRI screening is recommended for women with >20% lifetime breast cancer risk.
• Quantitative BPE measurement may provide additional risk stratification beyond classical models like Gail, Claus, and Tyrer-Cuzick.
• BPE levels vary with hormonal factors, breast density, and BRCA mutation status, but prior studies show conflicting results on BPE differences in BRCA carriers.

Guideline-Based Recommendations

Diagnosis

• Use combined mammography and breast MRI screening for women with lifetime breast cancer risk exceeding 20%.
• Calculate lifetime risk scores using models such as Tyrer-Cuzick to stratify patients.

Management

• Schedule MRI screening for high-risk women during the second week of the menstrual cycle to minimize estrogen-induced BPE variability.
• Exclude patients with prior breast cancer, mastectomy, or recent tamoxifen use when assessing BPE for risk evaluation.

Monitoring & Follow-up

• Quantitatively assess BPE using automated segmentation and deep learning methods to reduce inter-reader variability.
• Consider clinical factors such as age, BMI, menopausal status, hormonal therapy, and breast density when interpreting BPE.

Risks

• Recognize that BPE is hormone-sensitive and may fluctuate with menstrual cycle and menopausal status, potentially confounding risk assessment.
• Be aware of conflicting evidence regarding BPE differences in BRCA mutation carriers, necessitating cautious interpretation.

Patient & Prescribing Data

Women undergoing breast MRI screening, including nonhigh-risk, high-risk non-BRCA, and BRCA1/2 mutation carriers

Quantitative BPE measurements may aid in refining breast cancer risk stratification and tailoring screening protocols, but require adjustment for hormonal and clinical factors.

Clinical Best Practices

• Perform breast MRI screening in high-risk women in the second week of the menstrual cycle to reduce estrogen-related BPE variability.
• Utilize automated, quantitative methods for BPE assessment to improve reproducibility and accuracy over qualitative radiologist assessments.
• Incorporate clinical and genetic factors such as BRCA mutation status and menopausal status when interpreting BPE measurements.

References

• American Cancer Society Breast MRI Screening Guidelines
• Tyrer-Cuzick Breast Cancer Risk Model
• Background Parenchymal Enhancement and Breast Cancer Risk Studies
• BRCA1/2 Mutation Impact on Breast Cancer Risk